- Home
- KNF vs RCUS Comparison
KNF vs RCUS Comparison
Compare KNF & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KNF | RCUS |
|---|---|---|
| Founded | 1917 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.8B |
| IPO Year | 2023 | 2018 |
Fundamental Metrics
Financial Performance| Metric | KNF | RCUS |
|---|---|---|
| Price | $58.28 | $28.53 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 10 |
| Target Price | ★ $97.25 | $31.90 |
| AVG Volume (30 Days) | 720.8K | ★ 1.1M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,146,012,000.00 | $247,000,000.00 |
| Revenue This Year | $8.93 | N/A |
| Revenue Next Year | $5.28 | $45.62 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 8.52 | N/A |
| 52 Week Low | $58.72 | $11.30 |
| 52 Week High | $96.28 | $31.74 |
Technical Indicators
Market Signals| Indicator | KNF | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 27.53 | 43.54 |
| Support Level | N/A | $28.23 |
| Resistance Level | $80.09 | $29.08 |
| Average True Range (ATR) | 2.22 | 1.17 |
| MACD | -0.09 | -0.21 |
| Stochastic Oscillator | 0.10 | 7.69 |
Price Performance
Historical ComparisonAbout KNF Knife Riv Holding Co.
Knife River Corp is a people-first construction materials and contracting services company. It provides construction materials and contracting services to build safe roads, bridges, airport runways, and other critical infrastructure needs that connect people. The group is a provider of crushed stone, sand, and gravel in the United States. It operates through four reportable segments: West, Mountain, Central, and Energy Services.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.